Early clinical results from chemoradiation with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer

Clinical Colorectal Cancer

Volumn 7, Issue 5, 2008, Pages 325-330

  Lawson, Joshua D ^a   Kauh, John ^a   Koshy, Mary ^a   Staley, Charles ^a   Landry, Jerome ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abdominoperineal resection; Downstaging; Intensity modulated radiation therapy; Tumor node metastasis staging

Indexed keywords

ANTIBIOTIC AGENT; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTIBIOTIC THERAPY; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; COLITIS; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; INFECTION; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LIVER METASTASIS; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROSENSORY TOXICITY; NEUROTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; PERITONEUM METASTASIS; PREOPERATIVE TREATMENT; PROCTITIS; RADIATION DOSE; RECTUM CANCER; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 53849108111     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.043     Document Type: Article

References (27)

1. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985; 312:1465-72.
2. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324:709-15
3. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997; 336:980-7.
4. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731-40.
5. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
6. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-47.
7. Blackstock AW, Hess S, Chaney S, et al. 202 Oxaliplatin: In vitro evidence of its radiation sensitizing activity - preclinical observations relevant to clinical trials. Int J Rad Oncol Biol Phys 1999; 45:253-4.
8. Cividalli A, Ceciarelli F, Livdi E, et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002; 52:1092-8.
9. Yeh KH, Cheng AL, Wan JP, et al. Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. Anticancer Drugs 2004; 15:371-6.
10. Ramanathan RK, Clark JW, Kemeny NE, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 2003; 21:2904-11.
11. Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 1998; 25:23-31.
12. Bécouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998; 16:2739-44.
13. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 9:105-8.
14. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95-8.
15. Landry JC, Rosenthal D, Spitz F, et al. ECOG 1297: a phase I study of preoperative radiation therapy (RT) with concurrent protracted continuous infusion 5-FU and dose escalating oxaliplatin followed by surgery, adjuvant 5-FU, and leucovorin for locally advanced (T3/4) rectal adenocarcinoma. Int J Rad Oncol Biol Phys 2003; 57:S179.
16. Machiels JP, Duck L, Honhon B, et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 2005; 16:1898-905.
17. Rödel C, Grabenbauer GG, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21:3098-104.
18. Rödel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007; 25:110-7.
19. Ryan DP, Niedzwiecki D, Hollis D, et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006; 24:2557-62.
20. Carraro S, Roca EL, Cartelli C, et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys 2002; 54:397-402.
21. Gérard JP, Chapet O, Nemoz C, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 2003; 21:1119-24.
22. Freyer G, Bossard N, Romestaing P, et al. Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol 2001; 19:2433-8.
23. Gambacorta MA, Valentini V, Coco C, et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: phase I and II studies. Int J Radiat Oncol Biol Phys 2004; 60:139-48.
24. Glynne-Jones R, Sebag-Montefiore D, Maughan TS, et al. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006; 17:50-6.
25. Rutten H, Sebag-Montefiore D, Glynne-Jones R, et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study. J Clin Oncol 2006; 24:153s (Abstract 3528).
26. Czito BG, Bendell JC, Willett CG, et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 2007; 8:472-8.
27. Rödel C, Arnold D, Hipp M, et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008; 70:1081-6.